Analyst Reco. Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-02 pm EDT			5-day change	1st Jan Change
2.65 ^USD	-0.38%		-.--%	+11.81%

Jun. 13	Kinnate Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 03	Kinnate Biopharma Inc. Announces Board Resignations	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Stifel Raises Kinnate Biopharma's Price Target to $2.59 From $1.50, Keeps Hold Rating	Feb. 26	MT
Wedbush Adjusts Kinnate Biopharma's PT to $2.34 From $2 on Heels of Announced Sale Agreement With XOMA, Keeps Neutral Rating	Feb. 16	MT
Jefferies Cuts Price Target on Kinnate Biopharma to $2 From $31, Maintains Buy Rating	23-09-19	MT
HC Wainwright Downgrades Kinnate Biopharma to Neutral From Buy	23-09-19	MT
Wedbush Downgrades Kinnate Biopharma to Neutral From Outperform After News of Restructuring, Workforce Reduction; Cuts PT to $2 From $14	23-09-19	MT
Piper Sandler Downgrades Kinnate Biopharma to Neutral From Overweight, Cuts Price Target to $4 From $20	23-09-19	MT
HC Wainwright Adjusts Price Target on Kinnate Biopharma to $24 From $25, Keeps Buy Rating	23-05-18	MT
HC Wainwright Adjusts Price Target on Kinnate Biopharma to $25 From $33, Maintains Buy Rating	23-04-20	MT
Goldman Sachs Adjusts Price Target on Kinnate Biopharma to $26 From $29, Maintains Buy Rating	23-04-18	MT
Wedbush Lowers Kinnate Biopharma's PT to $14 From $25 After Adjusting Cost of Capital, Market Share Assumptions for Exarafenib; Keeps Outperform Rating	23-04-18	MT
Stifel Nicolaus Adjusts Kinnate Biopharma Price Target to $8 From $11, Maintains Hold Rating	23-03-16	MT
Wedbush Lowers Kinnate Biopharma's PT to $25 From $29 After Adjusting Market Share Assumptions for Exarafenib, KIN-3248; Keeps Outperform Rating	23-03-16	MT
Stifel Downgrades Kinnate Biopharma to Hold From Buy, Adjusts Price Target to $11 From $35	22-11-17	MT
Wedbush Lowers Kinnate Biopharma's Price Target to $29 From $33 Resulting From Adjustments to Cost of Capital, Keeps Outperform Rating	22-11-11	MT
HC Wainwright Initiates Kinnate Biopharma at Buy with $33 Price Target	22-07-28	MT
Goldman Sachs Adjusts Price Target for Kinnate Biopharma to $29 From $44, Reiterates Buy Rating	22-05-24	MT
Piper Sandler Adjusts Kinnate Biopharma's Price Target to $30 From $52, Reiterates Overweight Rating	22-05-19	MT
Wedbush Cuts Kinnate Biopharma's Price Target to $33 From $39, Citing Cost of Capital, Product Launch Estimates; Outperform Rating Kept	22-05-13	MT
Wedbush Adjusts Kinnate Biopharma's Price Target to $39 From $44, Citing Cost of Capital; Outperform Rating Kept	22-03-29	MT
Wedbush Adjusts Kinnate Biopharma's Price Target to $44 From $53, Citing Cost of Capital, Project Timelines; Outperform Rating Kept	22-01-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Analyst Reco.

Filters